Liliemark J - Search Results

1

Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia.

Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Danhauser L, et al. Among authors: liliemark j. Leukemia. 1987 Sep;1(9):638-43. Leukemia. 1987. PMID: 3478543

2

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Plunkett W, et al. Among authors: liliemark jo. Cancer Res. 1987 Jun 1;47(11):3005-11. Cancer Res. 1987. PMID: 3471322

3

Regulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in human leukemia cells by deoxycytidine 5'-triphosphate.

Liliemark JO, Plunkett W. Liliemark JO, et al. Cancer Res. 1986 Mar;46(3):1079-83. Cancer Res. 1986. PMID: 3484676

4

Pharmacologically directed ara-C therapy for refractory leukemia.

Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Plunkett W, et al. Among authors: liliemark jo. Semin Oncol. 1985 Jun;12(2 Suppl 3):20-30. Semin Oncol. 1985. PMID: 4012338

5

Relationship of 1-beta-D-arabinofuranosylcytosine in plasma to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate levels in leukemic cells during treatment with high-dose 1-beta-D-arabinofuranosylcytosine.

Liliemark JO, Plunkett W, Dixon DO. Liliemark JO, et al. Cancer Res. 1985 Nov;45(11 Pt 2):5952-7. Cancer Res. 1985. PMID: 4053067

6

Why do drugs work in CLL?

Plunkett W, Begleiter A, Liliemark JO, Reed JC. Plunkett W, et al. Among authors: liliemark jo. Leuk Lymphoma. 1996 Oct;22 Suppl 2:1-11. doi: 10.3109/10428199609102699. Leuk Lymphoma. 1996. PMID: 9021705 Review. No abstract available.

7

Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C.

Plunkett W, Liliemark JO, Estey E, Keating MJ. Plunkett W, et al. Among authors: liliemark jo. Semin Oncol. 1987 Jun;14(2 Suppl 1):159-66. Semin Oncol. 1987. PMID: 3589690 No abstract available.

8

Increasing the accumulation of daunorubicin in human leukemic cells by prolonging the infusion time.

Paul C, Tidefelt U, Liliemark J, Peterson C. Paul C, et al. Among authors: liliemark j. Leuk Res. 1989;13(2):191-6. doi: 10.1016/0145-2126(89)90145-8. Leuk Res. 1989. PMID: 2927175

9

Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity.

Gruber A, Liliemark E, Tidefelt U, Paul C, Björkholm M, Peterson C, Liliemark J. Gruber A, et al. Among authors: liliemark j, liliemark e. Leuk Res. 1995 Oct;19(10):757-61. doi: 10.1016/0145-2126(95)00061-r. Leuk Res. 1995. PMID: 7500654

10

Real-time RT-PCR for the determination of topoisomerase II mRNA level in leukaemic cells.

Zhou R, Frostvik Stolt M, Kronenwett U, Gruber A, Liliemark J, Liliemark E. Zhou R, et al. Among authors: liliemark j, liliemark e. Leuk Res. 2002 May;26(5):487-94. doi: 10.1016/s0145-2126(01)00144-8. Leuk Res. 2002. PMID: 11916525

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters